Skip to main content
Top
Published in: Clinical and Translational Oncology 3/2006

01-03-2006 | Research Articles

Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole

Authors: Emilio Alba, Antonio Llombart, Nuria Ribelles, Manuel Ramos, Roberto Fernández, José Ignacio Mayordomo, Ignasi Tusquets, Miguel Gil, Agustí Barnadas, Francisco Carabante, Manuel Ruiz, Ruth Vera, Isabel Palomero, Vicente Soriano, Jesús González, Ramón Colomer

Published in: Clinical and Translational Oncology | Issue 3/2006

Login to get access
Metadata
Title
Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole
Authors
Emilio Alba
Antonio Llombart
Nuria Ribelles
Manuel Ramos
Roberto Fernández
José Ignacio Mayordomo
Ignasi Tusquets
Miguel Gil
Agustí Barnadas
Francisco Carabante
Manuel Ruiz
Ruth Vera
Isabel Palomero
Vicente Soriano
Jesús González
Ramón Colomer
Publication date
01-03-2006
Publisher
Springer-Verlag
Published in
Clinical and Translational Oncology / Issue 3/2006
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-006-0010-3

Other articles of this Issue 3/2006

Clinical and Translational Oncology 3/2006 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine